Sanofi eyes new deals to boost vax biz

Sanofi-Aventis has been a big winner in the race to capitalize on the swine flu pandemic with a new vaccine, and today it tempted investors with plans to double its vaccine sales by 2013. Sanofi also echoed earlier remarks that it may turn to acquisitions to help bolster its vaccine business. Story

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.